Patents Issued in May 26, 2016
  • Publication number: 20160143959
    Abstract: The use of propolis or an extract of propolis as a food supplement for preventing and/or combating pathological conditions associated with diet-induced obesity, and in particular type II diabetes, and a specific a composition suitable for this use.
    Type: Application
    Filed: June 11, 2014
    Publication date: May 26, 2016
    Inventor: Nicolas CARDINAULT
  • Publication number: 20160143960
    Abstract: It was found that bacteria belonging to the genus Clostridium induce accumulation of regulatory T cells (Treg cells) in the colon. Moreover, the present inventors found that regulatory T cells (Treg cells) induced by from these bacteria suppressed proliferation of effector T-cells. From these findings, the present inventors found that the use of bacteria belonging to the genus Clostridium or a physiologically active substance derived therefrom made it possible to induce proliferation or accumulation of regulatory T cells (Treg cells), and further to suppress immune functions.
    Type: Application
    Filed: December 1, 2015
    Publication date: May 26, 2016
    Applicant: The University of Tokyo
    Inventors: Kenya Honda, Koji Atarashi, Kikuji Itoh, Takeshi Tanoue
  • Publication number: 20160143961
    Abstract: Probiotic compositions containing non-pathogenic microbial entities, e.g., bacterial or fungal entities, are described herein. The probiotic compositions may optionally contain or be used in conjunction with one or more prebiotics. Uses of the probiotic compositions to treat or prevent transplant disorders, e.g., graft-versus-host disease (GVHD), in a subject are also provided.
    Type: Application
    Filed: December 14, 2015
    Publication date: May 26, 2016
    Inventors: David Berry, Shaila Rahman, Noubar B. Afeyan, Johanne Kaplan, Neal Gordon
  • Publication number: 20160143962
    Abstract: Pharmaceutical compositions containing microbial entities are described herein. The pharmaceutical compositions may optionally contain or be used in conjunction with one or more prebiotics. Uses of the pharmaceutical compositions to treat or prevent disorders of the local or systemic microbiome in a subject are also provided.
    Type: Application
    Filed: November 25, 2015
    Publication date: May 26, 2016
    Inventors: David Berry, Johanne Kaplan
  • Publication number: 20160143963
    Abstract: The invention is applicable within the food and pharmaceutical industry. More specifically, it relates to a novel strain of the species Bifidobacterium animalis subsp. lactis CECT 8145, the cell components, metabolites and secreted molecules thereof, which, incorporated into food and/or pharmaceutical formulations, can be used in the treatment and/or prevention of excess weight and obesity and related diseases such as metabolic syndrome, hypertension, glycemia, inflammation, type 2 diabetes, cardiovascular diseases, hypercholesterolemia, hormonal alterations, infertility, etc.
    Type: Application
    Filed: July 17, 2014
    Publication date: May 26, 2016
    Inventors: Patricia MARTORELL GUEROLA, Mª Empar CHENOLL CUADROS, Daniel RAMÓN VIDAL, Pepa ORTIZ SERRANO, Silvia LLOPIS PLA, Núria GONZALEZ MARTÍNEZ, Salvador GENOVÉS MARTÍNEZ, Beatriz CASINOS RAMO, Ángela SILVA ANGULO, Amaya ALEIXANDRE
  • Publication number: 20160143964
    Abstract: The present finding relates to a composition comprising the probiotic Lactobacillus rhamnosus GG (ATCC 53103) for use in the prevention and/or treatment of herpes labialis and to a composition comprising the probiotic bacterial species and a soluble prebiotic fibre.
    Type: Application
    Filed: June 26, 2014
    Publication date: May 26, 2016
    Applicant: GRANAROLO S.P.A.
    Inventors: Andrea Borsari, Vittorio Angelo Zambrini
  • Publication number: 20160143965
    Abstract: The subject invention provides a pharmaceutical composition comprising: (i) at least one bacteriophage strain(s) capable of producing a lytic infection in an adherent-invasive Escherichia coli strain; and (ii) a pharmaceutically acceptable carrier; for the treatment of inflammatory bowel disease. The subject invention further provides a method of treating inflammatory bowel disease comprising administering to a subject in need thereof at least one bacteriophage strain capable of producing a lytic infection in an adherent-invasive Escherichia coli strain thereby treating the subject. The subject invention also provides new bacteriophage strains.
    Type: Application
    Filed: April 30, 2014
    Publication date: May 26, 2016
    Applicants: FERRING B.V., INSTITUT PASTEUR
    Inventors: Pascal Danglas, Laurent Debarbieux
  • Publication number: 20160143966
    Abstract: Methods for delivering a therapeutic agent to a cerebral cortex or to the cerebral cortex and spinal cord include administering a viral vector that includes the therapeutic agent into white matter of a brain in order to deliver the therapeutic agent to the cerebral cortex or to the cerebral cortex and spinal cord. Kits for performing such methods may include at least one viral vector, at least one therapeutic agent, and a convection enhanced delivery (CED) catheter.
    Type: Application
    Filed: May 16, 2014
    Publication date: May 26, 2016
    Applicant: RENISHAW PLC
    Inventors: Steven Streatfield GILL, Neil BARUA
  • Publication number: 20160143967
    Abstract: The present disclosure involves compositions and methods for treating brain cancers having mutations in the retinoblastoma (Rb) pathway using an oncolytic adenovirus comprising an alteration in the Rb binding site of E1A, and a targeting motif inserted in the Ad fiber protein. The adenovirus is able to kill the tumor cells without harming cells with a wild-type retinoblastoma pathway.
    Type: Application
    Filed: June 13, 2014
    Publication date: May 26, 2016
    Applicants: DNATRIX, Inc., Board of Regents, The University of Texas Systems
    Inventors: Juan FUEYO-MARGARETO, Candelaria MANZANO-GOMEZ, Charles CONRAD, Fred LANG, W.K. Alfred YUNG, Frank TUFARO
  • Publication number: 20160143968
    Abstract: The invention provides methods of reducing or decreasing a size of a tumor or eliminating a tumor by inhibiting, decreasing, or reducing neo-vascularization or angiogenesis in a tumor in a patient by administering an adenovirus comprising a nucleic acid construct comprising a FAS-chimera gene operably linked to an endothelial cell-specific promoter. Also provided is a homogeneous population of an adenovirus comprising a FAS-chimera gene operably linked to an endothelial cell-specific promoter and its uses thereof.
    Type: Application
    Filed: November 23, 2015
    Publication date: May 26, 2016
    Applicant: Vascular Biogenics Ltd.
    Inventors: Eyal BREITBART, Andrea Leubitz, Erez Feige
  • Publication number: 20160143969
    Abstract: A modified coxsackievirus showing improved safety and/or aggressiveness to be used for oncolytic virotherapy is provided. A modified coxsackievirus showing tissue-specific suppression of proliferation and comprising a imitated genome consisting of the genome of coxsackievirus B3 wild-type (CVB3-WT) inserted with at least one polynucleotide consisting of a target sequence of tissue-specific microR NA (miRNA) is provided. The mutated genome is preferably further inserted with the region encoding GM-CSF in an expressible form.
    Type: Application
    Filed: April 17, 2014
    Publication date: May 26, 2016
    Applicant: KYUSHU UNIVERSITY NATIONAL UNIVERSITY CORPORATION
    Inventors: Kenzaburo Tani, Shohei Miyamoto, Hiroyuki Inoue, Miyako Sagara
  • Publication number: 20160143970
    Abstract: Novel formulations are disclosed of a therapeutically effrective composition comprising two or more of an extract of Ganoderma lucidum, an extract of Salvia miltiorrhiza, an extract of Scutellaria barbata, and an extract of Scutellaria baicalensis wherein each extract comprises about 1 to about 90 percent by weight. Extracts are made in aqueous solvents, alcohol solvents and non-alcoholic organic solvents. Formulations comprising one or more emulsifiers demonstrating higher bioavailablity and maximum tolerated dose are provided.
    Type: Application
    Filed: June 3, 2014
    Publication date: May 26, 2016
    Inventors: James DAO, Jeffery DAO, Thomas DAO, David KWOK
  • Publication number: 20160143971
    Abstract: Methods for using botanical compositions comprising administration of non-alcoholic organic extracts of Ganoderma lucidum, Salvia miltiorrhiza, and Scutellaria barbata in conjunction with docetaxel for cancer therapy, are provided. Method for treatment or therapy of prostate cancer in a human is provided, the method comprising: administering an effective amount of the botanical composition during a period of administering concurrently an effective amount of docetaxel, wherein the concurrent administration of the docetaxel and the botanical composition achieves a therapeutic effect that is more effective than either agent alone.
    Type: Application
    Filed: June 3, 2014
    Publication date: May 26, 2016
    Inventors: James DAO, Jeffery DAO, William GERWICK, Lena GERWICK, MaryAnn JORDAN, Leslie WILSON
  • Publication number: 20160143972
    Abstract: Disclosed is a method of preparing a solid form of a cannabinoid. The solid form of the Cannabinoid may be substantially soluble in an aqueous solution. The method may include dissolving each of a Cannabinoid and one or more emulsifying agents into one or more solvents to obtain one or more combined solutions. Further, the method may include separating the one or more solvents from the one or more combined solutions to obtain the solid form of the cannabinoid.
    Type: Application
    Filed: November 23, 2015
    Publication date: May 26, 2016
    Applicant: Cannamark Inc.
    Inventors: Russell Hobart Stebbins, Derick Scott Anderson
  • Publication number: 20160143973
    Abstract: Disclosed is a method for preparing a red ginseng saponin extract. In the method, saponin components and non-saponin components are extracted from red ginseng and the non-saponin components are selectively removed from the red ginseng extract to prepare a red ginseng extract containing large amounts of the saponin components. According to the method, saponin components are extracted from red ginseng in high yield and non-saponin components are efficiently removed from the extract. Also disclosed is a red ginseng saponin extract prepared by the method. The red ginseng saponin extract is free of precipitable substances and putrefactive substances, such as starch and free sugars, and contains high-purity saponin components at high concentrations. The red ginseng saponin extract is prevented from being discolored and precipitated even after long-term storage, achieving good storage stability and high marketability.
    Type: Application
    Filed: October 27, 2015
    Publication date: May 26, 2016
    Inventor: Sun-sug KIM
  • Publication number: 20160143974
    Abstract: A method and formulation for delivering a sexual aid, such as epimedium or yohimbe, in a vaporized state using low temperatures to vaporize the formulation. The formulation contains an inert non-reactive compound that lowers the heat of vaporization of the formulation, and the active compound. The formulation may optionally contain glycerin, alcohol, and/or water. Examples of inert non-reactive compounds that can sufficiently lower the heat of vaporization of the formulation include propylene glycol, vegetable glycerin and polysorbate. The formulation can be vaporized using a hand-held low temperature vaporizer or atomizer.
    Type: Application
    Filed: January 27, 2016
    Publication date: May 26, 2016
    Inventors: Alexander Chinhak Chong, William P. Bartkowski, Marshall A. Thompson
  • Publication number: 20160143975
    Abstract: The invention relates to a method for producing triptolide from a suspension cell culture of Tripterygium sp., to a triptolide-enriched extract obtainable by means of extraction from the culture medium of an in vitro culture of dedifferentiated cells of the species Tripterygium, and to the therapeutic applications of said extract.
    Type: Application
    Filed: November 24, 2015
    Publication date: May 26, 2016
    Applicant: PIERRE FABRE MEDICAMENT
    Inventors: Nicolas STEWARD, Nadine CHOMARAT, Ngoc Thien N'GUYEN
  • Publication number: 20160143976
    Abstract: A traditional Chinese medicine composition for treating cardiovascular disease, and a preparation thereof, particularly a micro drop pill preparation thereof, and a method for preparing the preparation; the method for preparing the micro drop pill preparation can be used to prepare drop pills, coated drop pills, and drop pill capsules with a high drug loading capacity.
    Type: Application
    Filed: July 11, 2014
    Publication date: May 26, 2016
    Inventors: Xijun Yan, Naifeng Wu, Kaijing Yan, Zhengliang Ye, Shunnan Zhang, Lihong Zhou, Wensheng Zhang, Hai'ou Dong, Yongfeng Zheng, Lijun Fan
  • Publication number: 20160143977
    Abstract: Stabilized ophthalmic compositions containing omega-3 oils are provided, which are useful as artificial tears and as ophthalmic compositions to diagnose, treat, or prevent keratoconjunctivitis or dry eye syndrome in a human or other mammal.
    Type: Application
    Filed: November 23, 2015
    Publication date: May 26, 2016
    Inventors: Anuradha V. Gore, Jaya Giyanani, Sukhon Likitlersuang
  • Publication number: 20160143978
    Abstract: Disclosed herein are orally acceptable topical analgesic gels comprising a mixture of analgesic oils comprising (a) clove oil and/or eugenol, (b) a cooling agent, and (c) camphor, in an orally acceptable gel base, the gel base comprising an anionic polymer and a basic amino acid, and the analgesic gel providing controlled release of the mixture of analgesic oils following application to a tooth together with a methods of making and using the same.
    Type: Application
    Filed: March 7, 2013
    Publication date: May 26, 2016
    Inventors: Shashank Potnis, Ravi Subramanyam, Rajitha Nair
  • Publication number: 20160143979
    Abstract: In a preferred embodiment, there is provided a method for preparing a medicament for the treatment or prevention of a cancer, the method comprising: grinding a Piper plant or a plant component thereof to obtain a ground plant mixture or powder; soaking the ground plant mixture or powder in a solvent to obtain a suspension having a liquid extract portion and a plant solid portion; and separating the liquid extract portion from the plant solid portion to provide a separated liquid extract for use in the medicament.
    Type: Application
    Filed: November 16, 2015
    Publication date: May 26, 2016
    Inventors: Siyaram PANDEY, Pamela Uzuazo OVADJE
  • Publication number: 20160143980
    Abstract: A treatment regimen for psoriasis includes administering to a patient diagnosed with psoriasis periodic doses of a combination including Sheng Di Huang, Da Huang and Jin Yin Hua, or a combination of the above with Mu Dan Pi, Di Gu Pi, Xian He Cao and Chun Gen Pi.
    Type: Application
    Filed: November 19, 2015
    Publication date: May 26, 2016
    Inventor: Nadav Shraibom
  • Publication number: 20160143981
    Abstract: A conjugate of a titanium dioxide nanomaterial and nanoparticulate herbal and/or fruit extracts is synthesized by impregnation, using titanium dioxide as support, to which are adsorbed organic functional groups, inorganic radicals and plant extracts that confer thereon anti-microbial properties with high disinfectant and antiseptic power, removing bacteria, fungi, mycobacteria, spores, mycobacteria, protozoa and viruses. The conjugate is a solid nanomaterial in liquid suspension and is prepared by impregnation to disperse the functional groups and the extract particles, with temperature control to stabilize the interactions within the network of the support. Virucidal, bactericidal, fungicidal, mycobactericidal, mycoplasmicidal, antiprotozoal and sporicidal activity of the nanoparticulate biomaterial depends on the particle size of the support oxide, the functionalization and the dispersion of extracts adsorbed on the surface.
    Type: Application
    Filed: June 19, 2014
    Publication date: May 26, 2016
    Applicant: Inmolecule International Limited
    Inventor: Gabriela León Gutiérrez
  • Publication number: 20160143982
    Abstract: A preparation comprises a herbal extract and/or fraction, and a pharmaceutical preparation includes extract of Curcuma mangga Val. et Zipp., which has bioactivities in reducing expression levels of 5-alpha-reductase-1, androgen receptor, and PI3 in prostate cancer cells. The use of this present invention is directed to reduce prostate enlargement. Moreover, it also can be used to treat prostate cancer, lung cancer, and other diseases related to GPCR pathway.
    Type: Application
    Filed: June 3, 2014
    Publication date: May 26, 2016
    Inventors: Asep ARIPIN, Agung Heru KARSONO, Olivia MAYASARI, Prika HARDADI, James M. AMBELA, James M. SINAMBELA
  • Publication number: 20160143983
    Abstract: Disclosed are compositions comprising isolated peptides having a leucine content of from about 12 to about 40 weight percent. Also disclosed is a method for isolating leucine-rich peptides from protein sources such as bovine whey and methods of use for these peptides to provide beneficial effects in a human and/or animal such as increasing blood flow, decreasing blood pressure, increasing muscle mass, improving cognitive function, improving cardiovascular function, etc.
    Type: Application
    Filed: December 28, 2015
    Publication date: May 26, 2016
    Applicant: Glanbia Nutritionals (Ireland) Ltd.
    Inventors: Brent Petersen, Loren S. Ward, Eric D. Bastian, Stanley Wrobel
  • Publication number: 20160143984
    Abstract: Provided are methods and compositions from reprogramming human glial cells into human neurons. The reprogramming is achieved using combinations of compounds that can modify signaling via Transforming growth factor beta (TGF-?), Bone morphogenetic protein (BMP), glycogen synthase kinase 3 (GSK-3), and ?-secretase/Notch pathways. The reprogramming is demonstrated using groups of three or four compounds that are chosen from the group thiazovivin, LDN193189, SB431542, TTNPB, CHIR99021, DAPT, VPA, SAG, purmorphamine. Reprogramming is demonstrated using the group of LDN193189/CHIR99021/DAPT, the group of B431542/CHIR99021/DAPT, the group of LDN193189/DAPT/SB431542, the group of LDN193189/CHIR99021/SB431542, a three drug combination of SB431542/CHIR99021/DAPT. Reprogramming using functional analogs of the compounds is also provided, as are pharmaceutical formulations that contain the drug combinations.
    Type: Application
    Filed: November 25, 2015
    Publication date: May 26, 2016
    Inventors: Gong CHEN, Gang-Yi WU, Lei ZHANG, Jiu-Chao YIN, Hana YEH, Ning-Xin MA, Grace LEE
  • Publication number: 20160143985
    Abstract: The present disclosure provides ICE-cleaved alpha-synuclein fragments as biomarkers for alpha-synuclein-associated disease or disorder and/or for ICE-regulator therapy.
    Type: Application
    Filed: June 25, 2015
    Publication date: May 26, 2016
    Applicant: Brandeis University
    Inventors: Dagmar Ringe, Gregory A. Petsko, Quyen Hoang
  • Publication number: 20160143986
    Abstract: The present invention generally relates to systems and methods for the transdermal delivery of the heptapeptide ZW1. In some aspects, ZW1 may be contained with a composition comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, liquid crystals, or other configurations. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.
    Type: Application
    Filed: November 17, 2015
    Publication date: May 26, 2016
    Applicant: Transdermal Biotechnology, Inc.
    Inventor: Nicholas V. Perricone
  • Publication number: 20160143987
    Abstract: The present invention comprises methods of treating an infection using a pharmaceutical composition comprising an active ingredient selected from Table 1. In some aspects, the infection can be caused by one or more pathogens, including fungal pathogens. For example, the infection may be Valley Fever.
    Type: Application
    Filed: November 24, 2015
    Publication date: May 26, 2016
    Inventors: David Engelthaler, Elizabeth Driebe, Hongwei "Holly" Yin, Michael Valentine, Donald Chow, Jolene Bowers, Paul Keim
  • Publication number: 20160143988
    Abstract: Methods of treating an eye of a human or animal include administering to an eye of a human or animal a composition in the form of an emulsion including water, a hydrophobic component and a cyclosporin component in a therapeutically effective amount of less than 0.1% by weight of the composition. The weight ratio of the cyclosporin component to the hydrophobic component is less than 0.8.
    Type: Application
    Filed: January 29, 2016
    Publication date: May 26, 2016
    Inventors: Andrew Acheampong, Diane D. Tang-Liu, James N. Chang, David F. Power
  • Publication number: 20160143989
    Abstract: A composition comprises a water-soluble polymer matrix in which are dispersed droplets of oil, the composition comprising an active principle. The invention includes embodiments in which the active principle is included in at least some of the oil droplets as well as embodiments in which the oil droplets are free of active principle. The oil droplets are released as the matrix containing them dissolves in an aqueous medium. In one embodiment, the oil droplets are substantially immobilized in or by the matrix and the immobilizing feature is lost as the matrix dissolves in aqueous media. In certain embodiments, the oil drops may collectively be referred to as the oil phase of the composition of the invention. The product may be in the form of mini-beads. The oil phase and/or the polymer matrix may each include a surfactant.
    Type: Application
    Filed: January 29, 2016
    Publication date: May 26, 2016
    Applicant: Sigmoid Pharma Limited
    Inventors: Ivan Coulter, Bernard Francis McDonald, Vincenzo Aversa
  • Publication number: 20160143990
    Abstract: The invention relates to a topical composition containing a variant of an OB-fold protein, and also to the process for preparing the same.
    Type: Application
    Filed: April 22, 2014
    Publication date: May 26, 2016
    Inventor: Olivier Kitten
  • Publication number: 20160143991
    Abstract: Kits and methods for treating cancer comprising administration of a gliadin peptide to a patient are disclosed herein. A kit according to the invention comprises a pharmaceutical composition comprising a gliadin peptide and instructions for administering the peptide to a patient. The kit may further comprise a pharmaceutical composition comprising at least one chemotherapeutic agent such as a receptor tyrosine kinase inhibitor and instructions for co-administering the compounds. A method of treating cancer according to the invention comprises administering a gliadin peptide to a patient and may further comprise co-administering at least one chemotherapeutic agent such as a receptor tyrosine kinase inhibitor. Co-administration of a gliadin peptide and receptor tyrosine kinase inhibitor to a patient with cancer is effective to decrease or prevent resistance of the cancer to the receptor tyrosine kinase inhibitor.
    Type: Application
    Filed: January 26, 2016
    Publication date: May 26, 2016
    Applicant: BARMARSA RESEARCH LLC
    Inventor: Fred L. Shaw
  • Publication number: 20160143992
    Abstract: The invention in suitable embodiments is directed to purified clathrin protein therapeutics. In one aspect, one or more purified clathrin protein therapeutic, formed in whole or in part from isolated, synthetic and or recombinant amino acid residues comprising in whole or in part one or more clathrin heavy chain protein and isoforms thereof, forms one or more type of therapeutic agent for treating a psychiatric and/or neuropsychiatric disease, condition, or disorder, in vivo or in vitro.
    Type: Application
    Filed: January 27, 2016
    Publication date: May 26, 2016
    Inventors: FRANCO VITALIANO, GORDANA DRAGAN VITALIANO
  • Publication number: 20160143993
    Abstract: A method of treating autism spectrum disorders using a therapeutic amount of a synthetic amino acid sequence corresponding to a portion of human ciliary neurotrophic factor (CNTF). In particular, the synthetic amino acid sequence is VGDGGLFEKKL (SEQ ID NO: 1), referred to as Peptide 6. Peptide 6 was tested and shown to exert a neuroprotective effect by modulating CNTF/JAK/STAT pathway and LIF signaling and enhancing brain derived neurotrophic factor (BDNF) expression.
    Type: Application
    Filed: November 24, 2015
    Publication date: May 26, 2016
    Applicant: The Research Foundation for Mental Hygiene, Inc.
    Inventors: Khalid Iqbal, Inge Grundke-Iqbal
  • Publication number: 20160143994
    Abstract: Disclosed is the novel myokine known as myonectin (CTRP15) an isolated nucleic acid encoding the myonectin (CTRP15) gene, and the amino acid sequence encoding the myonectin (CTRP15) protein. Methods of isolation of the nucleic acid, protein, polypeptides and methods of making anybodies to myonectin (CTRP15) protein are provided. The use of myonectin (CTRP15) in the modulation of lipid and/or glucose metabolism, suppressing the expression of autophagy genes, inhibiting LC3 lipidation and autophagosome-dependent p62 degradation, and activating the Akt/mTOR pathway is also provided.
    Type: Application
    Filed: November 25, 2015
    Publication date: May 26, 2016
    Inventors: Guang William Wong, Marcus Michael Seldin
  • Publication number: 20160143995
    Abstract: The present invention provides a method of treating an intracellular infection in a subject wherein the method comprising administering to the subject an IAP antagonist. In certain embodiments the IAP antagonist is a Smac mimetic.
    Type: Application
    Filed: June 25, 2014
    Publication date: May 26, 2016
    Inventors: Marc Pellegrini, Gregor Klaus-Peter Ebert, Colin Glenn Begley
  • Publication number: 20160143996
    Abstract: The present invention provides methods for preventing, attenuating neuronal damage or stimulating neuronal repair prior or following central nervous system injury.
    Type: Application
    Filed: September 9, 2015
    Publication date: May 26, 2016
    Inventors: Jian Luo, Anton Wyss-Coray
  • Publication number: 20160143997
    Abstract: Therapies using IL-18 alone or in combination with IL-7 for rebuilding weakened immune systems by increasing progenitor cell yields from bone marrow stem cells and/or increasing stem cell engraftment in bone marrow.
    Type: Application
    Filed: November 20, 2015
    Publication date: May 26, 2016
    Inventors: Tracy Kent Teague, Jonathan D. Wren, Siva Kumar, Julie Harris Marino, Chibing Tan, Ashlee Allison Rempel, Charles Justin Van De Wiele
  • Publication number: 20160143998
    Abstract: The invention relates to a derivative of a GLP-1 analogue, optionally C-terminally extended, which derivative comprises a first and a second protracting moiety in the form of a C20 or C22 diacid radical, a bis-amino branched linker, and a first and a second further linker each comprising an OEG-like linker element; wherein these elements are interconnected via amide bonds and attached to a Lys residue of the GLP-1 analogue. The invention also relates to intermediate products in the form of novel GLP-1 analogues incorporated in the derivatives of the invention, as well pharmaceutical compositions and medical uses of the derivatives. The derivatives have very long half-lives while maintaining a satisfactory potency, which makes them potentially suitable for once-monthly administration.
    Type: Application
    Filed: June 19, 2014
    Publication date: May 26, 2016
    Inventors: Steffen Reedtz-Runge, Per Sauerberg, Jacob Kofoed, Ingrid Pettersson, Christian W. Tornoee
  • Publication number: 20160143999
    Abstract: The present disclosure relates to a method for treatment or prevention of diseases have an increased level of insulin-like growth factor I (IGF-I). The method comprises administration of a growth hormone (GH) variant having antagonistic activity in combination with an oligonucleotide targeted to growth hormone receptor (GHR) to a subject in need.
    Type: Application
    Filed: January 26, 2016
    Publication date: May 26, 2016
    Inventor: George Tachas
  • Publication number: 20160144000
    Abstract: Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.
    Type: Application
    Filed: January 28, 2016
    Publication date: May 26, 2016
    Inventor: Mir Imran
  • Publication number: 20160144001
    Abstract: The present invention provides compositions, systems, and methods for treating a condition characterized by elevated Fibroblast Growth Factor 23 (FGF23) with a composition comprising: i) an agent that causes an increase in expression of urokinase plasminogen activator (uPA) and/or tissue plasminogen activator (tPA), ii) purified uPA, and/or purified tPA.
    Type: Application
    Filed: November 23, 2015
    Publication date: May 26, 2016
    Inventors: Douglas E. Vaughan, Mesut Eren, Aaron T. Place, Toshio Miyata
  • Publication number: 20160144002
    Abstract: The present invention provides therapeutic mammalian cells which synthesize and express SS hemoglobin and a tumoricidal transgene. They are produced by transduction of SS erythroid progenitors/erythroblasts using viral vectors comprising a tumoricidal transgene operatively linked to the coding region of SS ?-globin promoter/enhancer. Such transduced SS erythroid cells differentiate into mature SSRBCs that exhibit sustained synthesis and expression of SS hemoglobin, a tumoricidal protein(s). Both mature and progenitor SS-cells carrying tumoricidal transgene(s) are capable of selectively localizing in tumor microenvironment, occluding tumor microvessels and inducing a tumoricidal response.
    Type: Application
    Filed: January 27, 2016
    Publication date: May 26, 2016
    Inventor: David S. Terman
  • Publication number: 20160144003
    Abstract: Provided are compositions and methods for the treatment of mutant glycyl-tRNA synthetase (GlyRS)-associated diseases, such as Charcot-Marie-Tooth (CMT) diseases, and related compositions and methods for diagnostic, drug discovery, and research applications. Also provided are mutant glycyl-tRNA synthetases and uses thereof.
    Type: Application
    Filed: May 17, 2012
    Publication date: May 26, 2016
    Applicant: THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Xiang-lei Yang, Paul Schimmel, Weiwei He
  • Publication number: 20160144004
    Abstract: A composition for removal of biofilm in the airway passage is useful for the treatment of infections such as pneumonia cause by Mycoplasma pneumoniae. In general, the composition comprises: (1) a quantity of at least one enzyme that catalyzes the hydrolysis of a bond that connects two monosaccharides in a polysaccharide or that connects a monosaccharide with a protein molecule in a glycoprotein sufficient to break down biofilm in the airway; and (2) a pharmaceutically acceptable carrier suitable for administration into the airway. The composition can further include ingredients such as a steroid, lysozyme, lactoferrin, or a peroxidase; if a peroxidase is included, the composition can further include an oxidase to generate peroxide as well as a substrate for the oxidase. The composition can be used in methods for treatment of an infection based on the ability of the composition to dissolve biofilm in the airway.
    Type: Application
    Filed: January 8, 2016
    Publication date: May 26, 2016
    Inventor: Michael Pellico
  • Publication number: 20160144005
    Abstract: Described herein is an association of at least one phosphate binder, at least one uremic toxin binder, at least one vasoactive antihypertensive agent and at least one antifibrotic agent for the management of progressive renal diseases including chronic kidney diseases (CKD) in domestic carnivores. Specifically, the application describes veterinarian compositions comprising such an association and the use thereof for the treatment of CKD conditions.
    Type: Application
    Filed: June 26, 2014
    Publication date: May 26, 2016
    Inventors: Natalia BERNACHON, Patricia MONGINOUX
  • Publication number: 20160144006
    Abstract: The present invention provides compositions, methods, and systems for treating inflammatory conditions (e.g., by inhibiting reactive oxygen species) in or on a subject with maspin, maspin derivatives, or maspin mimetics. In some embodiments, such agents are applied to the skin of a subject (e.g., to reduce skin aging).
    Type: Application
    Filed: November 19, 2015
    Publication date: May 26, 2016
    Inventor: Ming Zhang
  • Publication number: 20160144007
    Abstract: Techniques are disclosed for prevention or treatment of physiological shock by administering a specific therapeutic agent, which is able to use smaller volumes of reagent to achieve complete inhibition, than other previously described techniques.
    Type: Application
    Filed: January 29, 2016
    Publication date: May 26, 2016
    Inventors: Geert W. Schmid-Schoenbein, Frank A. DeLano
  • Publication number: 20160144008
    Abstract: A process is described for the production of an immunostimulant by submerged cultivation of Ganoderma lucidum in which mycelium from agar plates or a fermentation broth is added to a liquid medium in a shake flask or a bioreactor containing nutrients such as malt extract, yeast extract, peptone and glucose having access to air or to which air is added, and which is kept in constant movement at approx. 28° C. At the proper conditions, there will be an increase in the production of extracellular lentinan, which is shown to be a better immunostimulant than intracellular lentinan. The extracellular product is precipitated from the growth medium by means of methods for the precipitation of microbial polysaccharide.
    Type: Application
    Filed: January 28, 2016
    Publication date: May 26, 2016
    Inventor: Bjoern Kristiansen